标题
Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting
作者
关键词
-
出版物
DRUGS
Volume 78, Issue 2, Pages 215-229
出版商
Springer Nature
发表日期
2018-01-04
DOI
10.1007/s40265-017-0858-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care
- (2017) Olivier S. Descamps et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres
- (2017) Monika Kohli et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
- (2017) Kevin Fitzgerald et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
- (2017) Camilla Gustafsen et al. Nature Communications
- Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain
- (2017) Nathanael G. Lintner et al. PLOS BIOLOGY
- The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Nephrotic Syndrome-Associated HypercholesterolemiaClinical Perspective
- (2016) Mary E. Haas et al. CIRCULATION
- Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk FactorsCLINICAL PERSPECTIVE
- (2016) Karin Leander et al. CIRCULATION
- PCSK9 in diabetic kidney disease
- (2016) Usama Elewa et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
- (2016) Michel Farnier et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
- (2016) Brian A. Ference et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies
- (2016) Jacques Rey et al. Journal of the American Heart Association
- Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study
- (2015) Dean J. Kereiakes et al. AMERICAN HEART JOURNAL
- Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
- (2015) Christopher P. Cannon et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis
- (2015) Michael J. Koren et al. POSTGRADUATE MEDICINE
- Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study
- (2015) Jennie Lin et al. BMC Nephrology
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
- (2014) Gregory G. Schwartz et al. AMERICAN HEART JOURNAL
- Statin Intolerance
- (2014) Zahid Ahmad AMERICAN JOURNAL OF CARDIOLOGY
- Elevated Circulating PCSK-9 Concentration in Renal Failure Patients is Corrected by Renal Replacement Therapy
- (2014) Marcin Konarzewski et al. AMERICAN JOURNAL OF NEPHROLOGY
- Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels
- (2014) H. Abujrad et al. ATHEROSCLEROSIS
- Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials
- (2014) E. A. Stein et al. EUROPEAN HEART JOURNAL
- Cardiovascular disease in Europe 2014: epidemiological update
- (2014) Melanie Nichols et al. EUROPEAN HEART JOURNAL
- Looking into the Crystal Ball—Upcoming Drugs for Dyslipidemia
- (2014) Melvin George et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient
- (2014) Christoph Wanner et al. KIDNEY INTERNATIONAL
- Plasma Lipoprotein(a) Levels Are Associated with Mild Renal Impairment in Type 2 Diabetics Independent of Albuminuria
- (2014) Jennie Lin et al. PLoS One
- Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment
- (2014) Christian Werner et al. VASCULAR PHARMACOLOGY
- Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk
- (2013) Amit V. Khera et al. CIRCULATION
- Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes
- (2013) John J. Albers et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome
- (2013) S. Liu et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010
- (2013) Andreas Kuznik et al. BMC Nephrology
- Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent
- (2013) Alexandrios Briasoulis et al. Current Cardiology Reports
- Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial
- (2011) Z. Awan et al. CLINICAL CHEMISTRY
- Niacin: The Evidence, Clinical Use, and Future Directions
- (2011) Todd C. Villines et al. Current Atherosclerosis Reports
- The Peripheral Arterial disease study (PERART/ARTPER): prevalence and risk factors in the general population
- (2010) María Teresa Alzamora et al. BMC PUBLIC HEALTH
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
- (2010) Bin Dong et al. JOURNAL OF LIPID RESEARCH
- Major Lipids, Apolipoproteins, and Risk of Vascular Disease
- (2009) The Emerging Risk Factors Collaboration* JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Genetic and Metabolic Determinants of Plasma PCSK9 Levels
- (2009) Susan G. Lakoski et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database
- (2009) Philip J. Barter et al. JOURNAL OF LIPID RESEARCH
- Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment
- (2008) G. Lambert et al. CLINICAL CHEMISTRY
- Plasma PCSK9 levels are significantly modified by statins and fibrates in humans
- (2008) Janice Mayne et al. Lipids in Health and Disease
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now